Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN

Jefferies Financial Group Inc. acquired a new position in Urogen Pharma (NASDAQ:URGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,199,652 shares of the company’s stock, valued at approximately $80,947,000. Urogen Pharma comprises approximately 0.5% of Jefferies Financial Group Inc.’s portfolio, making the stock its 19th largest position. Jefferies Financial Group Inc. owned approximately 4.50% of Urogen Pharma at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Osaic Holdings Inc. raised its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. Russell Investments Group Ltd. grew its position in Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after buying an additional 3,125 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Urogen Pharma during the second quarter valued at about $66,000. Quantbot Technologies LP acquired a new position in Urogen Pharma in the 2nd quarter valued at approximately $78,000. Finally, Tower Research Capital LLC TRC raised its holdings in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after acquiring an additional 5,571 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on URGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. Oppenheimer lifted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Guggenheim boosted their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 6th. UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Finally, TD Cowen upped their target price on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and an average target price of $50.38.

Insider Transactions at Urogen Pharma

In other news, insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $47.05, for a total value of $2,854,852.85. Following the transaction, the insider owned 59,086 shares of the company’s stock, valued at approximately $2,779,996.30. This trade represents a 50.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 85,899 shares of company stock worth $3,747,513. Corporate insiders own 4.80% of the company’s stock.

Urogen Pharma Trading Down 1.0%

NASDAQ:URGN opened at $45.50 on Friday. The stock has a market capitalization of $2.22 billion, a P/E ratio of -22.98 and a beta of 1.57. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81. The firm has a 50 day moving average of $41.61 and a 200-day moving average of $29.85.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. As a group, analysts forecast that Urogen Pharma will post -0.2 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.